DistantNews
Support us
🇹🇼 Taiwan /Health & Science

Researchers Find Key to Pancreatic Cancer Cells' 'Invisibility' Cloak

From Liberty Times · () Chinese

Translated from Chinese, summarized and contextualized by DistantNews.

At a glance

News Sources not specified Context piece
  • Researchers have identified a key mechanism by which pancreatic cancer cells evade immune detection by shutting down specific identity signals.
  • A new study found that some pancreatic cancer cells turn off a gene called Tap1, which hinders T-cells from recognizing them as abnormal.
  • By combining strategies to restore these signals and block immune checkpoints, researchers successfully controlled tumor spread and extended survival in mouse models.

Pancreatic cancer, notoriously difficult to treat, has presented a significant challenge for immunotherapy. Now, a new study from the University of Minnesota Medical School offers a potential breakthrough by uncovering how some cancer cells "hide" from the immune system.

Part of pancreatic cancer cells actively turn off key identity signals, reducing the chance of being recognized by immune cells.

— Research TeamExplaining the mechanism of cancer cell evasion.

The research, published in Science Immunology, reveals that certain pancreatic cancer cells can deactivate a crucial gene, Tap1. This gene normally helps cells display protein fragments on their surface, acting as a signal for immune cells to identify abnormalities. When Tap1 is switched off, T-cells struggle to recognize and attack the cancer cells, effectively allowing the cancer to camouflage itself.

However, the study found that these "hidden" cancer cells are not entirely invisible. CD4 helper T-cells can still detect and control them. The problem arises when regulatory T-cells (Tregs) within the tumor suppress these CD4 cells, creating an "immune brake" that stifles the immune response.

The cancer cells do not simply 'become stronger,' but rather may turn off their identity signals to reduce the chance of being attacked by the immune system.

— Research TeamDescribing how cancer cells hide from immune detection.

To overcome this, the research team tested a dual approach in mouse models. They focused on both restoring the cancer cells' ability to display identification signals and blocking the CTLA-4 immune checkpoint to release the brake on CD4 cells. This combined strategy proved more effective than either treatment alone, significantly reducing tumor spread and prolonging survival in the mice.

CD4 helper T-cells can still recognize and control them.

— Research TeamIdentifying a specific immune cell type that can still target the cancer.

Analysis of human pancreatic tumors showed a correlation between the presence of CD4 helper T-cells and regulatory T-cells in the same areas and patient survival rates. While these findings are promising, the dual treatment has only been tested in preclinical models and requires further research to confirm its efficacy in treating human pancreatic cancer.

Tumor-infiltrating regulatory T-cells (Tregs) inhibit CD4 helper T-cells, creating another 'immune brake' that suppresses the immune response.

— Research TeamExplaining the 'immune brake' mechanism.
DistantNews Editorial

Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog